


# *SE IPAC Hub: HPE IPAC Lead CoP*

MAY 22, 2024



# *Group A Streptococcus (GAS) & Invasive Group A Streptococcus (iGAS)*

MAY 22, 2024



What did the pony say  
when she had a sore throat?



I'm a little horse!


LearnFunnyJokes.com



# Epidemiological Summary: iGAS in Ontario

October 1 2023 – March 31, 2024

- HPEPH reported highest average monthly rates
- 65 years+ highest incidence
- iGAS cases requiring hospitalization is slightly higher than the previous season
- *emm* types were available for 60% of cases in those 18+
- Most common *emm* types: *emm1*, *emm12*, *emm80*



DOPHS	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	2024 to date COUNT	2024 to date RATE per 1,000,000 population	5-year average year-to-date COUNT	5-year average year-to-date RATE
Group A Streptococcal Disease, Invasive	264	188	178										630	40.4	302	20.2

Resource: [Invasive Group A Streptococcal \(iGAS\) disease in Ontario: October 1, 2023 to March 31, 2024](#)

# What is Group A Streptococcus?

---

- Causative agent: *Streptococcus pyogenes* (bacteria)
- Gram-positive cocci, growing in pairs or chain
- Part of normal flora found in nares, throat or skin
- Can cause infections such as strep throat, scarlet fever, impetigo or cellulitis
- Individuals can be colonized or infected



# What is invasive Group A Streptococcus?

---

- Introduction of *Streptococcus pyogenes* in sterile part of the body
- Can cause septicemia, toxic shock syndrome (TSS) or necrotizing fasciitis (NF) and be life-threatening
- **Reportable to Public Health Unit**



# Risk Factors

---

- Open wounds or breaks in the skin (e.g. cuts, burns, sores, varicella or shingles)
- Chronic diseases (e.g. diabetes, pulmonary, hepatic or cardiac disease)
- Weakened immune system (immunosuppression) either from:
  - disease (HIV/AIDS)
  - cancer treatments (radiation, chemotherapy)
  - taking anti-rejection drugs following an organ or bone-marrow transplant
- Living in a crowded environment (e.g. dormitories, shelters, army barracks)
- Recent infection with chickenpox or with respiratory viruses such as influenza
- Substance use, including use of injectable drugs
- Recent close contact with someone with a GAS or iGAS infection
- During childbirth and in the post-partum period
- Occurs more often in young children <5 or adults aged >65+





# What signs and symptoms should I look for?

---

## GROUP A STREPTOCOCCUS

**Throat:** General feeling of un-wellness; fever and chills; sore red throat or tonsils; pain on swallowing; swollen/tender cervical lymph nodes; nausea or vomiting or diarrhea; headache, muscle aches

**Scarlet Fever:** red skin rash starting on face and neck and spreads; flushed face with paleness around mouth; red and bumpy tongue

**Impetigo:** itchy and red skin with blisters that crust and scab – typically around nose and mouth; swollen/tender lymph nodes; fever

**Cellulitis:** redness; warmth, swelling and tenderness or skin pain; swollen and tender lymph nodes; fever

## INVASIVE GROUP A STREPTOCOCCUS

**Septicemia:** fever; chills; headache; general feeling of un-wellness, tachycardia, tachypnea

**TSS:** hypotension; respiratory distress syndrome; generalized erythematous macular rash that may desquamate


**Soft tissue:** increasing severe pain and swelling; fever; redness around wound; can include NF, myositis or gangrene

**Meningitis:** fever; headache; stiff neck; nausea; vomiting; light sensitivity; confusion



# Additional Precautions

STREPTOCOCCAL DISEASE Group A <i>Streptococcus</i>	Skin, wound or burn infection, including necrotizing fasciitis	Droplet + Contact	Yes	Continue precautions until 24 hours of effective treatment.
	Toxic shock-like syndrome (TSLS)	Droplet + Contact	Yes	
	Pneumonia	Droplet	Yes	
	Pharyngitis/scarlet fever – paediatric*	Droplet	Yes	
	Endometritis (Puerperal Sepsis)	RP	No	
	Pharyngitis/ scarlet fever - adult	RP	No	



# Close Contacts

---

- Household contacts of a case who have spent at least 4 hours/day on average with the case in the previous 7 days
- Non-household persons who share the same bed with the case or had sexual relations with the case
- Persons who have had direct mucous membrane contact with the oral or nasal secretions of a case, such as mouth to mouth resuscitation, open mouth kissing or unprotected direct contact with an open skin lesion of the case
- Injection drug users who have shared needles with the case

# Testing in Long-Term Care

---

1. If a case of iGAS is confirmed, conduct a retrospective chart review. Look for:
  - Culture confirmed GAS cases
  - Suggested cases of GAS or iGAS, including skin and soft tissue and excluding pneumonia and conjunctivitis not confirmed by culture
2. If an **excess** of GAS infection identified, consider the following groups for testing:
  - All staff with positive history of suggested recent GAS infection
  - All residents in home <100 beds OR residents within the same unit as case
  - Contacts of case in homes with 100+ bed, within the unit
  - Suggested by resident or staff movements or epidemiological evidence
  - All patient care staff

# Specimen Collection




Blood agar plate showing beta-hemolysis of a *Streptococcus* culture



- C/S for *Streptococcus*
- Sources:  
Throat, rectal,  
nasal, vaginal,  
skin lesions
- Ambient  
temperature
- Submit to lab  
 $\leq 24$  hours

# iGAS and *emm* Typing

- Solid blood agar medium (or any other non-selective solid agar that support organism growth) OR
- Semi-solid charcoal transport swab




**PRIOR TO COLLECTION: CONFIRM SPECIMEN COLLECTION WITH YOUR PUBLIC HEALTH UNIT**

# Treatment

## Ontario Hospital Antibigram

% Susceptible 2018-2021 Data

[Consult the Technical Notes for details about how this antibiogram was prepared](#)



Resource: Ontario Hospital Antibigram (2022).

# Preventative Measures

---


- Passive screening
- Appropriate occupational health follow-up with staff
- Proper hand hygiene including following 4 moments of hand hygiene
- Proper cough and respiratory etiquette
- Cleaning and disinfecting shared equipment before and after each use
- Proper wound management
- Practicing point-of-care-risk assessment




# Outbreak Challenges

---

- Additional case identification = more specimens = greater workload = potential backlog of specimens = ...etc.
- Conflicting schedules of non-day, weekend only or agency staff
- Not able to cohort staff
- Private labs not work weekends/holidays and may affect TAT
- NML testing may affect TAT
- Consistent access to results
- IPAC lead coverage



# Outbreak Management



\*include: hand hygiene and 4 moments, PPE donning/doffing, aseptic technique and wound care, cleaning and disinfection, signs and symptoms

# Scenario

---

Felix, a resident of Fostergate Manor LTC, routinely goes for outings with his family during the week. He recently returned from a camping trip with his grandchildren who recently had strep throat. He has developed a sore throat and is now febrile. He typically experiences seasonal allergies. The nurse checks his vital signs and he has tachycardia and is hypotensive. The nurse also performs a head-to-toe and notices an older wound on his hand is swollen, tender and erythematous. The nurse asks Felix what happened to his hand and Felix, who is normally talkative, speaks few words and seems restless.

**What should next steps be?**



# Discussion

---

How do you feel about iGAS after this presentation?



# Reminders

---

- WhatsApp Group
- [IPAC Canada Membership](#)
- Summer Sessions



# Resources

---

- **Ministry of Health**  
[Appendix 1: Case Definition and Disease-Specific Information. Disease: Group A Streptococcal Disease, invasive \(iGAS\) \(2024\).](#)
- **Public Health Agency of Canada**  
[Group A \*Streptococcal\* disease: For health professionals](#)
- **Public Health Ontario**  
[Enhanced Epidemiological Summary: Invasive Group A Streptococcal \(iGAS\) Disease in Ontario: October 1, 2023 to March 31, 2024.](#) (2024).  
[Recommendations on Public Health Management of Invasive Group A Streptococcal \(iGAS\) Disease in Ontario](#) (2014).  
  
PIDAC: [Routine Practices and Additional Precautions in All Health Care Settings.](#) (2012). .
- Avire NJ, Whiley H, Ross K. [A Review of \*Streptococcus pyogenes\*: Public Health Risk Factors, Prevention and Control.](#) Pathogens. 2021 Feb 22;10(2):248.
- Metzgar D, Zampolli A. [The M protein of group A Streptococcus is a key virulence factor and a clinically relevant strain identification marker.](#) Virulence. 2011 Sep-Oct;2(5):402-12.
- Williams, J.L., Zembower, T.R. Addressing *Streptococci*. In: Dean R, Popescu S, eds. APIC Text. 2022. Available at [https://text.apic.org/toc/healthcare-associated-pathogens-and-diseases/streptococci#book\\_section\\_76698](https://text.apic.org/toc/healthcare-associated-pathogens-and-diseases/streptococci#book_section_76698) Accessed May 08, 2024.



# *Thank You*

TO CONTACT US, PLEASE EMAIL [SEHUBINTAKE@KINGSTONHSC.CA](mailto:SEHUBINTAKE@KINGSTONHSC.CA)